Nisoxetine hydrochloride
Nisoxetine hydrochloride structure
|
Common Name | Nisoxetine hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 57754-86-6 | Molecular Weight | 307.81500 | |
| Density | 1.054g/cm3 | Boiling Point | 404.8ºC at 760mmHg | |
| Molecular Formula | C17H22ClNO2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 170.6ºC | |
Use of Nisoxetine hydrochlorideNisoxetine hydrochloride is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.61 nM. Nisoxetine hydrochloride is an antidepressant and local anesthetic, it can block voltage-gated sodium channels[1][2][3]. |
| Name | Nisoxetine hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Nisoxetine hydrochloride is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.61 nM. Nisoxetine hydrochloride is an antidepressant and local anesthetic, it can block voltage-gated sodium channels[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Kd: 0.61 nM (NET)[1] |
| In Vitro | Nisoxetine inhibits [3H]Nisoxetine binding to rat frontal cortical membranes with a Ki of 1.4±0.1 nM[2]. Nisoxetine inhibits [3H]Noradrenaline uptake into rat frontal cortical synaptosomes with a Ki of 2.1±0.3 nM[2]. Nisoxetine inhibits Na+ currents with IC50s of 1.6 and 28.6 µM at the membrane potential of -70 and -100 mV, respectively[3]. |
| In Vivo | Nisoxetine (0.6-2.2 µM; a single intrathecal injection) displays dose-dependent effects on spinal anesthesia in rats[3]. Nisoxetine (2.2 µM; a single intrathecal injection) shows 100, 100, and 100% of blockades in motor function, proprioception, and with duration of action of about 61, 96, and 236 min, respectively[3]. Animal Model: Sprague-Dawley rats(290-340 g)[3] Dosage: 0.6, 1.2, 1.8, 2.2 µM Administration: A single intrathecal injection Result: With ED50s of 0.82 , 0.75 and 0.70 µM in motor function, proprioception, and nociception respectively. |
| References |
| Density | 1.054g/cm3 |
|---|---|
| Boiling Point | 404.8ºC at 760mmHg |
| Molecular Formula | C17H22ClNO2 |
| Molecular Weight | 307.81500 |
| Flash Point | 170.6ºC |
| Exact Mass | 307.13400 |
| PSA | 30.49000 |
| LogP | 4.61770 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Safety Phrases | S22-S26-S36 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2930909090 |
| HS Code | 2930909090 |
|---|---|
| Summary | 2930909090. other organo-sulphur compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|
Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.
Brain 138 , 3221-37, (2015) Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for which there is no effective treatment. Here we provide evidence that activation of serotonergic signalling is... |
|
|
The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes.
Neurochem. Res. 38(4) , 694-704, (2013) Pro-inflammatory cytokines have been implicated in the precipitation of depression and related disorders, and the antidepressant sensitive serotonin transporter (SERT) may be a major target for immune... |
|
|
Plasma membrane monoamine transporters: structure, regulation and function.
Nat. Rev. Neurosci. 4 , 13-25, (2003)
|
| MFCD00153850 |